Infosys Shares Drop Amid Earnings Quality Concerns 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Investors value green labels — but not always for the right reasons 
Wall Street Rebounds as Investors Eye Tariff Uncertainty, Jobs Report 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Tempus AI Stock Soars 18% After Pelosi's Investment Disclosure 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Tech Stocks Rally in Asia-Pacific as Dollar Remains Resilient 
South Korea to End Short-Selling Ban as Financial Market Uncertainty Persists 
SoftBank Eyes Up to $25B OpenAI Investment Amid AI Boom 
Elliott Investment Management Takes Significant Stake in BP to Push for Value Growth 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Investors Brace for Market Moves as Trump Begins Second Term 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
